Market closed · After hours · 7:04 PM ET
Last update: Nov 16, 2026, 6:14 PM ET
Market closed·101 changes confirmed today

Track the stock moves that actually matter.

BestStocks detects meaningful changes across price, volume, earnings, filings, valuation, analyst revisions, and risk signals — and shows you the evidence behind each one.

1,000 equities monitored14 signal typesCross-checked against SEC EDGARMedian detection lag ~41s
See all of today's movers: top gainers, losers and trending tickers →

Investment research built around change detection.

Showing:

BestStocks identifies what changed across companies and sectors, explains why it matters, and helps investors spot opportunities worth investigating.

✓After hours - Last update: Nov 16, 2026, 4:38 PM ET
POWL
Powell Industries, Inc.
$151.20
EPS surprise+42.04%
Nov 16, 2026 ET
🏆Material / Earnings✓High confidence

What changed: Powell Industries, Inc. (POWL) reported EPS of $2.23 vs. consensus estimate of $1.57, beating by 42.0% on 2026-11-16.

Source: earnings_events

Changes History →
What's next

Confirm the 2026-11-17 earnings announcement details and monitor forward guidance for FY2027 trajectory.

✓After hours - Last update: Nov 16, 2026, 4:46 PM ET
CGON
CG Oncology Inc.
$84.78
▼ 7.85%
Prev close $92.00
Nov 16, 2026 ET
🛡Material / Earnings✓High confidence

What changed: CG Oncology Inc. (CGON) moved -7.85% from $92.00 to $84.78 on 2026-11-16, one day after announcing positive Phase 3 PIVOT-006 trial results showing cretostimogene achieved 68% recurrence risk reduction in intermediate-risk and high-grade non-muscle-invasive bladder cancer. The stock initially rallied 14% on the news before reversing.

Source: daily_prices:fmp_change_percent

Changes History →
What's next

CG Oncology's BLA submissions scheduled for 2027 and FDA response timelines for the bladder cancer indication.

✓After hours - Last update: Nov 16, 2026, 4:38 PM ET
ARMK
Aramark
$55.43
▲ 7.74%
Prev close $51.45
Nov 16, 2026 ET
⚡Material / Earnings✓High confidence

What changed: Aramark (ARMK) moved +7.74% on 2026-11-16 after reporting Q4 FY2026 earnings. The company reported Q4 EPS of $0.71 versus a consensus estimate of $0.76, missing by 5.96%, but news sources highlighted that the quarter showed "unprecedented performance and positive momentum into fiscal 2027." Volume was 2.0x the 5-day average.

Source: daily_prices:fmp_change_percent

Changes History →
What's next

Aramark is scheduled to report earnings again on 2027-02-09 with a consensus EPS estimate of $0.64.

✓After hours - Last update: Nov 16, 2026, 4:38 PM ET
MOH
Molina Healthcare, Inc.
$233.09
▲ 9.34%
Prev close $213.17
Nov 16, 2026 ET
⚡Material / Earnings✓High confidence

What changed: Molina Healthcare, Inc. (MOH) moved +9.34% from $213.17 to $233.09 on 2026-11-16, reaching a new 30-day high on significantly elevated volume (2.9x the 5-day average).

Source: daily_prices:fmp_change_percent

Changes History →
What's next

MOH earnings scheduled for 2026-02-04 (consensus EPS estimate $0.52) will be a key test of whether the November momentum reflects improving fundamentals.

✓After hours - Last update: Nov 16, 2026, 10:08 AM ET
TSN
Tyson Foods, Inc.
$63.95
EPS surprise+14.66%
Nov 16, 2026 ET
🏆Material / Earnings✓High confidence Research available →

What changed: Tyson Foods, Inc. (TSN) reported EPS of $0.61 vs. $0.53 estimate, beating consensus by 14.7%.

Source: earnings_events

Changes History →
What's next

Monitor TSN's next earnings announcement and any guidance updates on pricing power and input costs.

✓After hours - Last update: Nov 16, 2026, 4:47 PM ET
ESAB
ESAB Corporation
$79.15
▼ 5.48%
Prev close $83.74
Nov 16, 2026 ET
🛡Material / Earnings✓High confidence

What changed: ESAB Corporation (ESAB) moved -5.48% from $83.74 to $79.15 on 2026-11-16. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, suggesting the move was not driven by unusual trading activity.

Source: daily_prices:fmp_change_percent

Changes History →
What's next

Monitor for ESAB earnings announcement on 2026-02-19 and any interim news that may explain the recent price action.

✓After hours - Last update: Nov 16, 2026, 4:44 PM ET
RYTM
Rhythm Pharmaceuticals, Inc.
$107.48
▼ 5.08%
Prev close $113.23
Nov 16, 2026 ET
🛡Material / Earnings✓High confidence

What changed: Rhythm Pharmaceuticals, Inc. (RYTM) moved -5.08% from $113.23 to $107.48 on 2026-11-16. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The decline occurred on volume near its 5-day average.

Source: daily_prices:fmp_change_percent

Changes History →
What's next

RYTM earnings scheduled for 2026-02-25 (preliminary date) will reveal whether operating losses are tracking consensus expectations.

✓After hours - Last update: Nov 16, 2026, 4:39 PM ET
IONS
Ionis Pharmaceuticals, Inc.
$28.01
▼ 6.42%
Prev close $29.93
Nov 16, 2026 ET
🛡Material / Earnings✓High confidence

What changed: Ionis Pharmaceuticals, Inc. (IONS) moved -6.42% from $29.93 to $28.01 on 2026-11-16 after TRYNGOLZA sales collapsed 71% year-over-year to $9.3M, triggering a shareholder lawsuit alleging securities violations.

Source: daily_prices:fmp_change_percent

Changes History →
What's next

IONS earnings scheduled for 2026-02-24, where management will likely address the TRYNGOLZA decline and litigation exposure.

✓After hours - Last update: Nov 16, 2026, 4:39 PM ET
PODD
Insulet Corp.
$145.38
▼ 5.29%
Prev close $153.50
Nov 16, 2026 ET
🛡Material / Earnings✓High confidence

What changed: Insulet Corp. (PODD) moved -5.29% from $153.50 to $145.38 on 2026-11-16. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The move occurred on modestly elevated volume (1.7x the 5-day average).

Source: daily_prices:fmp_change_percent

Changes History →
What's next

Insulet is scheduled to report earnings on 2027-02-17 (consensus EPS estimate: $1.74).

✓After hours - Last update: Nov 16, 2026, 4:39 PM ET
SPXC
SPX Technologies, Inc.
$146.08
▼ 5.14%
Prev close $154.00
Nov 16, 2026 ET
🛡Material / Earnings✓High confidence

What changed: SPX Technologies, Inc. (SPXC) moved -5.14% from $154.00 to $146.08 on 2026-11-16. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was identified. The move occurred on below-average volume (0.8x the 5-day average).

Source: daily_prices:fmp_change_percent

Changes History →
What's next

Watch for SPXC earnings on 2027-02-23 (consensus EPS estimate $2.49) to gauge execution against market expectations.

✓After hours - Last update: Nov 16, 2026, 4:38 PM ET
DDOG
Datadog, Inc.
$172.86
▼ 5.24%
Prev close $182.41
Nov 16, 2026 ET
🛡Material / Earnings✓High confidence

What changed: Datadog, Inc. (DDOG) moved −5.24% from $182.41 to $172.86 on 2026-11-16. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move coincided with DDOG reaching a new 30-day low; volume remained near its 5-day average.

Source: daily_prices:fmp_change_percent

Changes History →
What's next

DDOG earnings announcement on 2027-02-09 (consensus EPS estimate: $0.69).

✓After hours - Last update: Nov 16, 2026, 11:12 AM ET
ASTS
AST SpaceMobile, Inc.
$28.58
▼ 12.33%
Prev close $32.60
Nov 16, 2026 ET
📊Valuation✓High confidence

What changed: AST SpaceMobile fell 7.64% to $30.11, driven by a combination of broader space-sector weakness—with peers Rocket Lab and Firefly also declining—and pre-conference caution ahead of an investor conference starting November 17 where the market expects concrete updates on commercial service timelines and the Rakuten venture (Benzinga). Volume reached 5.58M shares, 1.29x the intraday average, signaling elevated trading activity.

Detected Nov 16, 3:50 PM ET

Source: Benzinga ↗

Changes History →
What's next

AST SpaceMobile investor conference (November 17 onwards) for commercial service schedule confirmation, satellite production expansion details, and Rakuten partnership specifics; Q4 2026 earnings announcement and guidance (scheduled March 1, 2027).

Latest research

View all research →

In-depth equity research from the BestStocks desk — earnings breakdowns, valuation deep dives, and sector analysis behind the changes we detect.

Summit Therapeutics (SMMT) share-price line falling sharply on an abstract background, marking an FDA Complete Response Letter for ivonescimab.
Stock AnalysisNovember 16, 2026 · 12 min read

Summit Therapeutics (SMMT) Plunges ~16% to a 52-Week Low After the FDA Rejects Ivonescimab's First US Filing

Summit Therapeutics plunged about 16% to roughly $11.82 — a fresh 52-week low — on November 16 after disclosing that the FDA had issued a Complete Response Letter (a rejection, for now) for its lead drug, ivonescimab. The move was emphatically company-specific: on a day the broad market and biotech indexes each fell about 2%, Summit dropped eight times as hard. The CRL covers ivonescimab plus chemotherapy after EGFR-targeted treatment in non-small cell lung cancer, from the Phase 3 HARMONi trial — which clearly met its progression-free survival goal (6.8 vs 4.4 months) but whose primary overall-survival analysis narrowly missed significance (16.8 vs 14.0 months, HR 0.79, p=0.057), and the FDA judged the benefit-risk insufficient. Crucially, this is not a verdict that the drug fails to extend life: in a separate first-line trial (China's HARMONi-2) ivonescimab beat Keytruda on overall survival (30.8 vs 22.6 months, HR 0.73, p=0.009). Several things keep the CRL from being thesis-ending: it covers one smaller indication; the far larger global first-line opportunity (HARMONi-3, HARMONi-7) is still ahead; and just six weeks earlier AstraZeneca completed a $2 billion strategic investment in Summit. Even after the drop, Summit is a ~$9.4 billion company with roughly $2.6 billion of liquidity (including the AstraZeneca cash) and ~27%-of-float short interest — a well-funded, AstraZeneca-backed, polarizing bet whose value rests almost entirely on first-line survival data still to come.

Tyson Foods (TSN) share-price line rising on an abstract background, marking a better-than-feared Q4 and a 2027 beef-recovery outlook.
Stock AnalysisNovember 16, 2026 · 11 min read

Tyson Foods (TSN) Jumps ~7% on a Better-Than-Feared Q4 and an Outlook for Sharply Narrower Beef Losses

Tyson Foods jumped about 7% to roughly $62.80 on November 16 after reporting fiscal fourth-quarter results — and it did so on a risk-off day, with the S&P 500 down nearly 2% as the AI, chip and crypto trades sold off. For a defensive consumer-staples name to rise ~7% while the market fell is a clear company-specific signal, reinforced by a rotation into cheap, low-beta stocks. Tyson's adjusted EPS of $0.61 was roughly in line with or slightly above commonly cited consensus estimates, but it was down ~47% year over year, and on a GAAP basis the company posted a $0.22-per-share loss; revenue of $14.6 billion beat but underlying sales fell ~4%, and adjusted operating income dropped 41%. What drove the jump was the outlook — specifically for beef: management guided its Beef segment from a $654 million fiscal-2026 loss toward roughly breakeven in 2027 (a $300 million loss to a $100 million profit), a sharp narrowing of the biggest drag on earnings caused by a historic cattle shortage, even though total-company adjusted operating-income guidance ($1.7–$2.15 billion) is roughly flat versus this year's $1.977 billion. The stock looks cheap on sales (~0.4x) and reasonable on forward earnings (~16x), but after the pop it sits right at the analysts' average target with a Hold rating — so the move reads as a weak-but-better-than-feared quarter plus a credible beef-loss turn, re-rating a beaten-down defensive in one session.

NVIDIA (NVDA) share-price line turning sharply lower on an abstract background, marking the abrupt resignation of co-founder CEO Jensen Huang.
Stock AnalysisNovember 13, 2026 · 12 min read

Nvidia (NVDA) Slides as Jensen Huang Abruptly Resigns as CEO, Days Before Earnings

NVIDIA fell about 3% to roughly $161 on November 13, slipping back below a $4 trillion market value, as the market digested a sudden and unexpected leadership change: co-founder Jensen Huang has resigned as President, CEO and board member, effective immediately. The Board named longtime CFO Colette Kress interim CEO and appointed Harvey C. Jones as its first-ever Chair, while launching a search for a permanent chief. NVIDIA's transition release gave no reason; days earlier, Mr. Huang had acknowledged an affair and the board had launched an independent investigation into a reported foreign-intelligence targeting (ongoing and unproven), and lawmakers have since sought his testimony. Because NVIDIA anchors the entire AI trade, the turmoil added to an already fragile tape — AMD fell ~10.5%, Broadcom ~5.4% and the semis ETF ~4%, versus less than 1% for the S&P 500. The timing is delicate: NVIDIA reports fiscal Q3 (FY2027) results on November 17, so one of tech's most closely watched prints will be delivered by an interim CEO days into an unexpected leadership transition. The franchise looks intact — ~$303B trailing revenue, ~20x earnings — so the sell-off reads as a repricing of leadership and governance risk rather than any newly reported operating weakness.

An abstract visualization of a rising stock chart over a wafer-scale chip grid motif in green tones, representing Cerebras's jump on a Q3 beat-and-raise and a hyperscaler deal even as the broader AI sector sold off.
Stock AnalysisNovember 13, 2026 · 12 min read

Cerebras (CBRS) Jumps ~7% on a Q3 Beat and a Hyperscaler Deal, Bucking the AI Selloff

Cerebras Systems rose about 7% to roughly $104.50 on November 13 after reporting third-quarter results — and what made it notable was the backdrop: the same day, the broader AI and chip trade sold off hard, with Nvidia down 3.5%, the semiconductor ETF down more than 4% and AMD down about 10%. For a richly valued AI name to rise while its sector cratered is a clear sign the move was its own news. Cerebras — maker of dinner-plate-sized 'wafer-scale' chips built to challenge Nvidia — beat its own guidance for a third straight quarter, raised its full-year outlook, flagged a cloud deal with a top-three hyperscaler (unnamed in the release, reportedly Microsoft) and projected revenue will triple in 2027, with a $26 billion backlog. But the quarter must be read carefully: the most flattering numbers are non-GAAP. Cerebras highlights 'core' revenue up 70% to about $231 million and a core net profit near $30 million, but on a GAAP basis revenue rose 55% to $210.8 million and the company posted a $161 million net loss. The gap is real — 'core' revenue is higher than GAAP because it adds back customer-warrant amortization, and the 'core' profit excludes heavy stock compensation. The company is cash-rich (about $7.8 billion), so financing is not the worry, but it is deeply GAAP-unprofitable, heavily reliant on a few customers including OpenAI, and trades near 30 times sales. Even bullish analysts cut their targets on the print (UBS to about $155), while keeping Buy ratings. A strong quarter bought a day of outperformance in a weak tape — but the hardest questions about the business are still open.

An abstract visualization of a sharply rising stock chart over a cooling-fins and heat-exchanger motif in green and cyan tones, representing Modine's surge on an unconfirmed report that Samsung is in talks to acquire the data-center cooling specialist.
Stock AnalysisNovember 13, 2026 · 11 min read

Modine (MOD) Surges ~31% on a Report Samsung Is in Talks to Buy It

Modine Manufacturing surged about 31% to roughly $139 on November 13 after Bloomberg reported the day before that Samsung Electronics is in talks to acquire the company — a maker of the thermal and liquid cooling systems that keep AI data centers from overheating. The appeal is strategic: as AI chips run hotter, data-center cooling has become a critical bottleneck, and Modine has reinvented itself into a focused, fast-growing pure-play, separating its legacy business (combining it with Gentherm) in October while data-center sales jumped about 95% in its most recent quarter. But the crucial point is what this is not: it is not a deal. Bloomberg's report says the talks could come together in weeks but that no final decision has been made, the discussions could fall through, and another buyer could emerge — and no offer price, terms or premium have been reported, with neither company confirming. The widely cited $5.6 billion figure is essentially Modine's market value before the report, not an agreed price, and the stock has already jumped above that level, to about $7.4 billion, as traders price in a premium that has not been offered. The move was company-specific: cooling peers were flat to lower, with the sector leader Vertiv actually down, so there is no read-through to competitors. Analysts rated the stock Strong Buy even before the report, though their targets were cut sharply after a fiscal Q2 earnings miss and predate any deal. In short, the surge is real but rests on a report, not terms; from here the stock trades as a bet on the outcome of private talks.